Immune Thrombocytopenia Treatment, also known as immune thrombocytopenic purpura or ITP, occurs when the immune system mistakenly attacks and destroys platelets. Platelets are blood cell fragments that help control bleeding. The exact cause…
Tag: corticosteroids
Ependymoma Drug Market Is Expected To Be Fueled By Increasing Research And Development Activities
The global Ependymoma Drug Market is estimated to be valued at US$ 172.64 Bn in 2024 and is expected to exhibit a CAGR of 7.7% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Alopecia Treatment Market is Expected to be Flourished by Growing Awareness Regarding Treatment Options
The most common forms of alopecia include androgenetic alopecia (male- and female-pattern baldness), alopecia areata, and telogen effluvium. Some commonly used treatment options include topical creams or solutions, injections, surgery, and drugs….
Lupus Therapeutic Market Promises Growth Owing to Rising Prevalence of Autoimmune Diseases
Lupus is a chronic inflammatory autoimmune disease that occurs when the body’s immune system attacks its own tissues and organs. It can damage any part of the body like joints, skin, kidneys,…
Growing Demand For Dairy Products Is Anticipated To Open Up New Avenue For The Bovine Mastitis Market
Staphylococcus aureus and Streptococcus agalactiae are some of the most predominant bacteria that cause mastitis in dairy cattle. The condition reduces milk production and increases somatic cell count in milk. Mastitis detection…
The Anti-Inflammatory Drugs Market Is Expected To Be Flourished By The Rising Prevalence Of Inflammatory Diseases
The global Anti-Inflammatory Drugs Market is estimated to be valued at US$ 102248.44 Mn in 2023 and is expected to exhibit a CAGR of 8.6% over the forecast period from 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
JAK Inhibitors and Tocilizumab Show Promise in Treating VEXAS Syndrome
New research presented at the annual meeting of the American College of Rheumatology (ACR) has revealed that JAK inhibitors (JAKi) and tocilizumab have demonstrated higher response rates in the treatment of VEXAS…